News

Keyword Search

Year

Jun 14, 2022

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , June 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted an equity award to a new employee as an equity inducement award outside of the Company's Amended and Restated

Jun 10, 2022

CTI BioPharma Presents Pivotal Data from Pacritinib Program at the European Hematology Association (EHA) 2022 Congress

SEATTLE , June 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced two scientific poster presentations from the Company's pacritinib clinical program at the European Hematology Association (EHA) 2022 Congress , being held in Vienna, Austria , June 9-12, 2022 .

Jun 02, 2022

CTI BioPharma to Present at Upcoming June Conferences

SEATTLE , June 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in New York City . Presentation details: Event: Jefferies Healthcare Conference Date: Friday, June 10, 2022 Time: 10:00

May 27, 2022

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , May 27, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated

May 26, 2022

CTI BioPharma Presents Pivotal Data from Pacritinib Program at the 2022 American Society of Clinical Oncology Annual Meeting

SEATTLE , May 26, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced a poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2022 .

May 12, 2022

CTI BioPharma Reports First Quarter 2022 Financial Results

– Strong U.S. commercial launch of VONJO™ (pacritinib) underway following accelerated FDA approval for the treatment of adult patients with Myelofibrosis and Thrombocytopenia – – VONJO (pacritinib) net product revenue of $2.3 million in less than one month following launch, exceeding initial

May 10, 2022

CTI BioPharma Announces Presentation at the 2022 American Society of Clinical Oncology Annual Meeting

SEATTLE , May 10, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced one poster presentation from the Company's pacritinib program at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, being held in Chicago and virtually, June 3-7, 2021 .

May 05, 2022

CTI BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SEATTLE , May 5, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that the Compensation Committee of its Board of Directors granted equity awards to two new employees as equity inducement awards outside of the Company's Amended and Restated 2017 Equity Incentive Plan (but

Apr 28, 2022

CTI BioPharma to Report First Quarter 2022 Financial Results on May 12, 2022

SEATTLE , April 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. ( CTI BioPharma ) (NASDAQ: CTIC) today announced that management plans to report its first quarter 2022 financial results on Thursday, May 12, 2022 , after the close of the U.S. financial markets.

Apr 14, 2022

NCCN Guidelines® Recommend VONJO™ (pacritinib) for the Treatment of Myeloproliferative Neoplasms

VONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count SEATTLE , April 14, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that VONJO™ (pacritinib), its novel oral kinase inhibitor with specificity for JAK2 and

Pagination

Current page 1
Page 2
Next page
Last page

Investors

News

News

Keyword Search

–

–

–

–